Patient SatisfactionNCT01131715
Pharmacist Follow-up, a Qualitative Study of Patient Experience
An observational study of Patient Satisfaction and Patient Preference, run by Hospital Pharmacy of North Norway Trust at 1 site in Norway.
Trial summary
A pharmacist follow-up procedure is under development. Patients with coronary heart disease (CHD) is being followed up by a pharmacist for one year with three meetings; at discharge from hospital, after three months and after one year. Read more about this study
- Who is it for?
- Ages 18 to 80 years
- Conditions the study is for
- Patient Satisfaction, Patient Preference
- How many people
- 4 participants
- Where
- 1 siteNorway
- Study dates
- Feb 2010to Jul 2012
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 80 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients included in the study "Pharmacist follow-up of patients with CHD".
Who may be able to join
- must have met the pharmacist at least twice
- living within the area of Tromsoe city so that interviews are possible
Who cannot join
- none as patients are already enrolled in another study
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Pharmacist Follow-up of Patients With Coronary Heart Disease. A Qualitative Study of Patient Experience.
A pharmacist follow-up procedure is under development. Patients with coronary heart disease (CHD) is being followed up by a pharmacist for one year with three meetings; at discharge from hospital, after three months and after one year. The evaluation is basically based on quantitative measures as achievement of therapeutic goals, number of drug related problems detected, hospitalisations etc. However, the patients' own experience with the follow-up procedure cannot be evaluated using these measures. Thus, a qualitative approach is needed. In this study, a total of four patients participating in the follow-up will be included and interviewed. A semistructured interview guide will be used. Interviews will be taped, transcribed and analyzed with the intention to explore how patients experience the follow-up from the pharmacist. A thoruough content analysis will be performed. Patients included must have met the pharmacist at least twice. The pharmacist in charge of the follow-up will recruit patients and hand out study information. Patients will reply to the principal investigator of the study and thus kept anonymous for the pharmacist in charge of the follow-up. No pressure will be put on the patients to join, but it will be emphasized that it will help evaluating the procedure.
Read the detailed description
See full publication on http://www.biomedcentral.com/1756-0500/7/197 Garcia et al. BMC Research Notes 2014, 7:197
- Conditions
- Patient Satisfaction, Patient Preference
- Keywords
- Qualitetive interview, Coronary heart disease (CHD), Patient experience, Patient perception
- Medical subject headings
- Patient Satisfaction, Patient Preference, Coronary Disease
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Study group | Patients who are included in the pharmacist follow-up procedure |
What is being measured
The primary outcome is the main question the study is designed to answer.
Qualitative evaluation of the impact of pharmacist follow-up via interviews with the participating patients
In the pharmacist follow-up procedure under development, patients have individual "consultations" with a pharmacist three times. Patients are recruited to this study at the second or third consultation. Interviews will be performed with patients included to explore how patients' experience this follow-up procedure. Outcome measures from patient interviews can be counted. In qualitative research, the content of the interviews are thoroughly analysed with focus on the meaning of the informant's/interviewee's sayings. Outcomes will be presented as overall themes touched by the informants.
Measured: 3 months or 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 May 2010 (estimated)
- Study startFeb 2010
- Primary completionMar 2010
- Study completionJul 2012
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Patient SatisfactionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Other
- Enrolment
- 4 participants (actual)
Sponsor and investigators
- Lead sponsor
- Hospital Pharmacy of North Norway Trust
- Sponsor type
- University, hospital or other
- Collaborators
- University of Tromso
- Responsible party
- Principal investigator, Beate Hennie Garcia, PhD, Hospital Pharmacy of North Norway Trust
- Investigators
- Lars Smaabrekke, PhD, Principal investigator, University of TromsoBeate H Garcia, PhD, Study chair, Hospital Pharmacy of North Norway Trust
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01131715
- Sponsor's protocol ID
- SHAN-002
- Status last verified
- Jun 2020
- First submitted
- 30 Apr 2010
- Last updated
- 29 Jun 2020
- Results posted
- No
- Data monitoring committee
- No
Publications
Garcia BH, Storli SL, Smabrekke L. A pharmacist-led follow-up program for patients with coronary heart disease in North Norway--a qualitative study exploring patient experiences. BMC Res Notes. 2014 Mar 29;7:197. doi: 10.1186/1756-0500-7-197.
PubMed 24679131
Study at a glance
From the registry record, last updated by the sponsor on 29 Jun 2020. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Pharmacist Follow-up of Patients With Coronary Heart Disease. A Qualitative Study of Patient Experience.
- ClinicalTrials.gov ID
- NCT01131715
- Acronym / sponsor ID
- SHAN-002
- Conditions
- Patient Satisfaction, Patient Preference
- Keywords
- Qualitetive interview, Coronary heart disease (CHD), Patient experience, Patient perception
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 4 participants (actual)
- Lead sponsor
- Hospital Pharmacy of North Norway TrustUniversity, hospital or other
- Collaborators
- University of Tromso
- Study start
- Feb 2010 (actual)
- Primary completion
- Mar 2010 (actual)
- Study completion
- Jul 2012 (actual)
- First posted
- 27 May 2010 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
A pharmacist follow-up procedure is under development. Patients with coronary heart disease (CHD) is being followed up by a pharmacist for one year with three meetings; at discharge from hospital, after three months and after one year. The evaluation is basically based on quantitative measures as achievement of therapeutic goals, number of drug related problems detected, hospitalisations etc. However, the patients' own experience with the follow-up procedure cannot be evaluated using these measures. Thus, a qualitative approach is needed. In this study, a total of four patients participating in the follow-up will be included and interviewed. A semistructured interview guide will be used. Interviews will be taped, transcribed and analyzed with the intention to explore how patients experience the follow-up from the pharmacist. A thoruough content analysis will be performed. Patients included must have met the pharmacist at least twice. The pharmacist in charge of the follow-up will recruit patients and hand out study information. Patients will reply to the principal investigator of the study and thus kept anonymous for the pharmacist in charge of the follow-up. No pressure will be put on the patients to join, but it will be emphasized that it will help evaluating the procedure.
Detailed description
See full publication on http://www.biomedcentral.com/1756-0500/7/197 Garcia et al. BMC Research Notes 2014, 7:197
Study design
- Observational model
- Other
- Time perspective
- Other
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Study group | – | –Patients who are included in the pharmacist follow-up procedure |
Who may qualify
- Ages
- 18 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients included in the study "Pharmacist follow-up of patients with CHD".
Key inclusion criteria (2 listed)
- must have met the pharmacist at least twice
- living within the area of Tromsoe city so that interviews are possible
Key exclusion criteria (1 listed)
- none as patients are already enrolled in another study
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Qualitative evaluation of the impact of pharmacist follow-up via interviews with the participating patients
Time frame: 3 months or 1 year
In the pharmacist follow-up procedure under development, patients have individual "consultations" with a pharmacist three times. Patients are recruited to this study at the second or third consultation. Interviews will be performed with patients included to explore how patients' experience this follow-up procedure. Outcome measures from patient interviews can be counted. In qualitative research, the content of the interviews are thoroughly analysed with focus on the meaning of the informant's/interviewee's sayings. Outcomes will be presented as overall themes touched by the informants.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 29 Jun 2020.
- Derived from this study: PubMed 24679131Garcia BH, Storli SL, Smabrekke L. A pharmacist-led follow-up program for patients with coronary heart disease in North Norway--a qualitative study exploring patient experiences. BMC Res Notes. 2014 Mar 29;7:197. doi: 10.1186/1756-0500-7-197.
- Published articleLink provided by the sponsor.
Related trials for Patient Satisfaction
Not yet recruiting
Effect of Stress Ball Use During Femoral Arterial Sheath Removal After Coronary Angiography
Femoral Arterial Sheath Removal, Stress Ball
Recruiting
Hybrid mHealth and Telerehabilitation vs Conventional Physiotherapy for Subacromial Pain Syndrome
Subacromial Pain Syndrome
RecruitingObservational study
A Study to Evaluate Patient-Reported Satisfaction, Effectiveness, and Safety of Atezolizumab in Participants Treated in Routine Clinical Practice
Lung Cancer, Hepatocellular Carcinoma
Recruiting
Effect of Mandala Coloring on Anxiety, Pain, Vital Signs, and Patient Satisfaction in Patients Undergoing Transurethral Resection of the Prostate
Mandala Coloring
Not yet recruiting
Feasibility of a Web-based Single-session Intervention Combined With Ecological Momentary Assessment and Intervention for Patients With Complex Posttraumatic Stress Disorder Awaiting Inpatient Treatment
PTSD - Post Traumatic Stress Disorder, Depression
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Lars Smaabrekke, PhD principal investigator
University of Tromso
Beate H Garcia, PhD study chair
Hospital Pharmacy of North Norway Trust
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Patient Satisfaction and Patient Preference, run by Hospital Pharmacy of North Norway Trust at 1 site in Norway.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 29 Jun 2020. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Norway. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Qualitative evaluation of the impact of pharmacist follow-up via interviews with the participating patients (time frame: 3 months or 1 year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT01131715, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Jun 2020.